Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1687
interventional 1327
Observational 336
Registry 24

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 844
Drug|placebo 209
Behavioral 61
Other 38
Biological|Drug 35
Biological 28
Biological|Drug|placebo 21
Device 13
Procedure 12
Diagnostic Test 8
Dietary Supplement 8
Behavioral|Other 6
Behavioral|Drug 4
Device|Drug 4
Biological|Other 3
Biological|placebo 3
Device|Other 3
Dietary Supplement|Drug 3
Drug|Other 3
Drug|Procedure 3
Behavioral|Biological 2
Biological|Drug|Other 2
Dietary Supplement|placebo 2
Drug|Other|placebo 2
Other|Procedure 2
placebo 2
Behavioral|Diagnostic Test 1
Behavioral|Procedure 1
Biological|Drug|Procedure 1
Diagnostic Test|Drug 1
Drug|Other|Procedure 1
Drug|placebo|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 358
NA 225
United States|Puerto Rico 55
Japan 45
Egypt 40
China 33
France 31
Canada 27
Taiwan 27
Spain 25
United Kingdom 21
Netherlands 20
Germany 16
Australia 13
Belgium 13
Iran, Islamic Republic of 13
Brazil 12
New Zealand 11
Russian Federation 11
United States|Canada 10
Korea, Republic of 9
India 8
Italy 8
Switzerland 7
Israel 6
Austria 5
Pakistan 5
Sweden 5
Australia|New Zealand 4
Norway 4
Puerto Rico 4
United States|Australia|Canada|France|Germany|New Zealand|Puerto Rico|United Kingdom 4
United States|New Zealand|Puerto Rico 4
Vietnam 4
China|Korea, Republic of|Taiwan 3
United States|France 3
Belgium|France 2
China|Korea, Republic of 2
Cuba 2
Czech Republic 2
Denmark 2
Georgia 2
Rwanda 2
Saudi Arabia 2
Thailand 2
United States|Australia|New Zealand|Puerto Rico 2
United States|Canada|New Zealand|Puerto Rico 2
United States|Canada|Puerto Rico 2
United States|France|Germany|Spain 2
United States|France|Puerto Rico 2
United States|Germany|New Zealand 2
United States|New Zealand 2
Algeria|Australia|Austria|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Argentina|Australia|Canada|Mexico|New Zealand|Thailand 1
Argentina|United States|Australia|Belgium|Canada|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Mexico|Poland|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|Thailand|United Kingdom|Vietnam 1
Australia|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|New Zealand|Spain|Switzerland|United Kingdom 1
Australia|Austria|United States|Canada|France|Germany|Italy|Puerto Rico|Spain 1
Australia|Belgium|Canada|Germany|Norway|Switzerland|United Kingdom 1
Australia|Brazil|France|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Australia|Canada|Czech Republic|France|Germany|Israel|Poland|Romania 1
Australia|Canada|France|Germany|Greece|India|Italy|Poland|Spain|Taiwan|Thailand|United Kingdom 1
Australia|France 1
Australia|France|Germany|Italy|Spain|United Kingdom 1
Australia|Germany|Poland|Romania|Spain|Taiwan 1
Australia|New Zealand|United Kingdom 1
Australia|United Kingdom 1
Austria|Belgium|France|Germany|Japan|Portugal|Romania|Russian Federation|Spain|Switzerland|United Kingdom 1
Austria|Belgium|France|Germany|Netherlands|Spain 1
Austria|Belgium|France|Germany|Saudi Arabia|Spain|United Kingdom 1
Austria|Belgium|France|Germany|Spain|United Kingdom 1
Austria|Brazil|France|Greece|Indonesia|Italy|Turkey|United Arab Emirates 1
Austria|Estonia|France|Germany|Italy|Netherlands|Poland|Spain|Sweden|United Kingdom 1
Austria|France|Germany|Italy 1
Austria|France|Germany|United Kingdom 1
Austria|Germany|Hungary|Poland|Romania|Spain 1
Belarus|India|Russian Federation|Thailand 1
Belgium|Brazil|France|Austria|United States|Australia|Germany|Ireland|Mexico|Poland|Spain|Sweden|United Kingdom 1
Belgium|Canada|Germany|Poland|Singapore|Spain 1
Belgium|France|Germany|Hungary|Spain|United Kingdom 1
Belgium|France|Germany|Italy|Poland|Romania|Spain 1
Belgium|France|Germany|United Kingdom 1
Belgium|Germany 1
Belgium|Germany|Hungary|Ireland|Luxembourg|Portugal|Russian Federation|United Kingdom 1
Belgium|Germany|Thailand 1
Belgium|Germany|United Kingdom 1
Belgium|Mauritius|Moldova, Republic of 1
Belgium|Moldova, Republic of 1
Belgium|Netherlands 1
Bulgaria|Israel|Romania 1
Cameroon|Côte D’Ivoire|Senegal 1
Canada|United States|Argentina|Australia|Austria|France|Germany|Ireland|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
Canada|United States|Austria|Brazil|France|Germany|Italy|Mexico|Puerto Rico|Spain|United Kingdom 1
China|Hong Kong|Korea, Republic of|Taiwan|Vietnam 1
China|Korea, Republic of|Russian Federation 1
China|Korea, Republic of|Singapore 1
China|Malaysia|Singapore|Thailand|Vietnam 1
Colombia 1
Czech Republic|France|Germany|Italy|Poland|Spain|Sweden|United Kingdom 1
Czech Republic|Korea, Republic of|Mexico 1
Czechia|Slovakia 1
Estonia|Russian Federation 1
France|Belgium|Germany|Netherlands|Poland|United Kingdom 1
France|Denmark|United States|Australia|Austria|Belgium|Canada|Germany|New Zealand|Norway|Poland|Russian Federation|Spain 1
France|Georgia|Moldova, Republic of 1
France|Germany|Greece|Italy|Spain 1
France|Germany|Netherlands 1
France|Germany|Switzerland 1
France|Germany|United States|Canada|Italy|Puerto Rico|Spain 1
France|Italy|Switzerland 1
France|Moldova, Republic of|Romania 1
France|Netherlands|Poland 1
France|New Zealand|Poland 1
France|Sweden|United Kingdom 1
France|United States|Australia|Austria|Belgium|Canada|Germany|New Zealand|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
France|United States|Belgium|Brazil|Canada|Denmark|Germany|Hungary|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Sweden|United Kingdom 1
Germany|Israel|Mexico|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|France|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Spain|Ukraine|United Kingdom 1
Germany|Netherlands 1
Germany|Poland|Romania 1
Germany|Poland|Spain 1
Germany|Poland|Sweden|United Kingdom 1
Germany|Serbia|United States|Argentina|Belgium|Chile|Egypt|Estonia|France|Greece|Italy|Kuwait|Latvia|Lebanon|Lithuania|Macedonia, The Former Yugoslav Republic of|Mexico|Oman|Pakistan|Peru|Portugal|Qatar|Romania|Slovakia|Sweden|Switzerland|Syrian Arab Republic|Taiwan|Turkey|United Arab Emirates|Venezuela 1
Germany|United Kingdom 1
Germany|United States 1
Germany|United States|Australia|Austria|Canada|France|Italy|Puerto Rico|Spain|United Kingdom 1
Germany|United States|Australia|Belgium|France|Hungary|Italy|Poland|Puerto Rico|Romania|Spain|Taiwan|Turkey|United Kingdom 1
Germany|United States|Australia|Canada|France|Italy|New Zealand|Puerto Rico|United Kingdom 1
Germany|United States|Austria|Canada|France|Netherlands|Puerto Rico|United Kingdom 1
Hong Kong 1
Indonesia|Malaysia|Thailand|Vietnam 1
Ireland|Switzerland 1
Israel|United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|India|Korea, Republic of|Malaysia|Mexico|Poland|Puerto Rico|Singapore|Spain|Sweden|Taiwan|Thailand|United Kingdom 1
Italy|Portugal|United States|Belgium|Brazil|Canada|France|Germany|Greece|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Italy|United States|Argentina|Australia|Belgium|Canada|France|Germany|Hong Kong|Hungary|India|Korea, Republic of|Mexico|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|Turkey|United Kingdom|Vietnam 1
Kazakhstan 1
Kenya 1
Korea, Republic of|Russian Federation|Taiwan 1
Korea, Republic of|Taiwan|Thailand 1
Lebanon 1
Malaysia|Thailand 1
Mauritius|Moldova, Republic of|New Zealand|United Kingdom 1
Mauritius|United Kingdom 1
Mexico 1
Mexico|United States|Australia|Canada|Denmark|Egypt|France|Germany|Italy|Puerto Rico|Sweden 1
Moldova, Republic of 1
Myanmar 1
Poland 1
Russian Federation|Sweden 1
Russian Federation|United States|Argentina|Australia|Belgium|Chile|Finland|France|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Singapore|Taiwan|United Kingdom 1
Spain|Sweden|Puerto Rico|Poland|United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Israel|Netherlands|Switzerland|United Kingdom 1
Spain|Switzerland|United Kingdom 1
Ukraine 1
United Kingdom|Australia|Canada|Israel|New Zealand|Spain 1
United States|Argentina 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Czech Republic|Denmark|France|Germany|Greece|Hungary|Israel|Norway|Poland|Portugal|Puerto Rico|Romania|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|Denmark|France|Germany|Israel|Italy|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|Czech Republic|France|Germany|Korea, Republic of|Netherlands|Portugal|Romania|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|Denmark|France|Germany|Greece|Ireland|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|France|Germany|Israel|Italy|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|Italy|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Australia|Canada|Denmark|France|Germany|Italy|Mexico|Puerto Rico|Sweden 1
United States|Argentina|Australia|Canada|France|Israel|Italy|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Bulgaria|France|Germany|Netherlands|Poland|Portugal|Puerto Rico|Slovakia|Spain|Turkey 1
United States|Argentina|Belgium|Canada|France|Germany|Italy|Mexico|Poland|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Canada|Denmark|France|Germany|Italy|Korea, Republic of|Mexico|Netherlands|Russian Federation|Spain|Sweden|Switzerland|Taiwan 1
United States|Argentina|Canada|Puerto Rico 1
United States|Argentina|France|Germany|Hungary|Spain 1
United States|Argentina|France|Germany|Ireland|Italy|Spain|United Kingdom 1
United States|Argentina|France|Germany|Israel|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Germany|Mexico|Puerto Rico|Switzerland 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Israel|New Zealand|Norway|Poland|Portugal|Russian Federation|United Kingdom 1
United States|Australia|Austria|Brazil|Canada|France|Germany|Italy|Mexico|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Austria|Canada|Czech Republic|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Canada|Czech Republic|France|Germany|India|Israel|Italy|Poland|Puerto Rico|Romania|Spain|United Kingdom 1
United States|Australia|Austria|Canada|France|Germany|Italy 1
United States|Australia|Austria|France|Germany|New Zealand|Portugal|Romania|Spain|Switzerland 1
United States|Australia|Belgium|Brazil|Canada|Czech Republic|France|Germany|Hong Kong|India|Israel|Italy|Korea, Republic of|Netherlands|Pakistan|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|France|Germany|Israel|Netherlands|Poland|Puerto Rico|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Greece|Italy|New Zealand|Portugal|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|India|Italy|Korea, Republic of|Poland|Puerto Rico|Taiwan|Thailand|United Kingdom 1
United States|Australia|Belgium|Canada|France|New Zealand|Singapore|South Africa|Vietnam 1
United States|Australia|Belgium|Canada|Germany|New Zealand|Puerto Rico|United Kingdom 1
United States|Australia|Belgium|Germany|Italy|New Zealand|Russian Federation|United Kingdom 1
United States|Australia|Belgium|Germany|Puerto Rico|Spain|Taiwan 1
United States|Australia|Brazil|Canada|China|Germany|Korea, Republic of|New Zealand|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Brazil|France|Greece|Italy|Poland|Puerto Rico|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Czechia|Germany|Israel|Korea, Republic of|Malaysia|New Zealand|Puerto Rico|Romania|Russian Federation|Singapore|Taiwan 1
United States|Australia|Canada|Denmark|France|Italy 1
United States|Australia|Canada|France 1
United States|Australia|Canada|France|Germany|Greece|Italy|Pakistan|Spain 1
United States|Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Spain 1
United States|Australia|Canada|France|Germany|New Zealand|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|New Zealand|Switzerland|United Kingdom 1
United States|Australia|Canada|France|Germany|New Zealand|United Kingdom 1
United States|Australia|Canada|France|New Zealand|Poland|Slovakia 1
United States|Australia|Canada|France|Puerto Rico 1
United States|Australia|Canada|Germany|Mexico|New Zealand|Puerto Rico|Romania|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Australia|Canada|Germany|Netherlands|New Zealand|Switzerland|United Kingdom 1
United States|Australia|Canada|Italy|Netherlands|New Zealand|Puerto Rico|Sweden 1
United States|Australia|Canada|New Zealand|Puerto Rico 1
United States|Australia|Canada|New Zealand|United Kingdom 1
United States|Australia|France|Germany|Italy|Japan|New Zealand|Puerto Rico|Spain 1
United States|Australia|France|Italy|Netherlands|Romania|Russian Federation|Spain 1
United States|Australia|France|New Zealand|Spain 1
United States|Australia|France|Puerto Rico|Spain 1
United States|Australia|Germany|New Zealand|Poland 1
United States|Australia|New Zealand 1
United States|Australia|New Zealand|United Kingdom 1
United States|Australia|Puerto Rico 1
United States|Austria|Belgium|Brazil|Canada|Czechia|France|Germany|Israel|Italy|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|Canada|Czech Republic|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Japan|Korea, Republic of|Portugal|Romania|Russian Federation|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Japan|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|France|Germany|Netherlands|Poland|United Kingdom 1
United States|Austria|Canada|France|Germany|Hungary|Ireland|Italy|Netherlands|Portugal|Romania|Russian Federation|Spain|United Kingdom 1
United States|Austria|Canada|France|Germany|Romania 1
United States|Austria|Canada|France|Germany|Spain 1
United States|Belgium 1
United States|Belgium|Brazil|Canada|Colombia|France|Germany|Italy|Korea, Republic of|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Belgium|Bulgaria|France|Germany|Puerto Rico 1
United States|Belgium|Canada|China|France|Germany|Italy|Puerto Rico|United Kingdom 1
United States|Belgium|Canada|France|Germany|Hong Kong|Italy|Puerto Rico|United Kingdom 1
United States|Belgium|Canada|France|Germany|Hungary|Korea, Republic of|Puerto Rico|Spain 1
United States|Belgium|Canada|France|Germany|Poland|Russian Federation 1
United States|Belgium|Canada|Germany|Japan|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Belgium|Germany|Ireland|Poland|Puerto Rico|United Kingdom 1
United States|Belgium|Germany|Italy|Taiwan 1
United States|Belgium|Germany|Puerto Rico|Spain 1
United States|Belgium|Italy|United Kingdom 1
United States|Belgium|Netherlands|Puerto Rico 1
United States|Brazil|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Brazil|France|New Zealand|Sweden 1
United States|Brazil|Puerto Rico|South Africa|Thailand|Uganda 1
United States|Bulgaria|Canada|Czechia|France|Greece|Hungary|Ireland|Israel|Italy|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|United Kingdom|Vietnam 1
United States|Bulgaria|Canada|France|Germany|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Bulgaria|Puerto Rico|Romania 1
United States|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Canada|France|Germany|Portugal|Puerto Rico|Spain|United Kingdom 1
United States|Canada|Germany 1
United States|Canada|Germany|Greece|Italy|Korea, Republic of|Poland|Puerto Rico|Spain|Sweden 1
United States|Canada|Germany|Netherlands|Puerto Rico 1
United States|Canada|Germany|Poland|United Kingdom 1
United States|Canada|Korea, Republic of|Puerto Rico|Taiwan 1
United States|Canada|United Kingdom 1
United States|Czechia|France|Germany|Hungary|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Denmark|United Kingdom 1
United States|France|Germany|Italy|Puerto Rico|Spain|United Kingdom 1
United States|France|Germany|New Zealand 1
United States|France|Germany|New Zealand|Spain 1
United States|France|Germany|Puerto Rico|United Kingdom 1
United States|France|Greece|Italy|Puerto Rico|Spain|United Kingdom 1
United States|Germany 1
United States|Germany|Netherlands 1
United States|Germany|Netherlands|Poland|Puerto Rico|Slovakia 1
United States|Germany|Poland|Sweden 1
United States|Germany|Spain|United Kingdom 1
United States|India|Australia|Belgium|Brazil|Canada|Czech Republic|Egypt|France|Germany|Greece|Israel|Italy|Korea, Republic of|Pakistan|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Taiwan|Ukraine 1
United States|New Zealand|Spain 1
United States|Russian Federation 1

Sites per Study

Site_count Study_Count
1 712
2 79
3 47
4 39
5 33
6 24
7 18
8 22
9 10
10 15
11 18
12 6
13 7
14 7
15 13
16 12
17 7
18 12
19 14
20 7
21 8
22 7
23 6
24 8
25 9
26 7
27 4
28 7
29 1
30 3
31 4
32 7
33 2
34 6
35 5
36 2
37 5
38 7
39 2
40 3
41 4
42 3
43 7
44 1
45 3
46 1
48 6
49 4
50 2
51 4
52 2
53 3
55 2
56 2
59 1
60 1
61 1
62 2
63 3
64 1
66 3
67 4
68 1
70 1
71 2
72 2
73 3
75 1
76 1
77 2
78 3
79 1
80 1
81 1
82 1
86 2
87 2
88 1
91 1
93 3
97 2
98 1
100 2
101 2
102 1
104 2
106 1
107 1
109 1
113 1
114 1
116 3
119 1
121 1
124 1
132 1
142 1
144 1
147 1
159 1
165 1
175 1
184 1
187 1
191 1
210 1
227 1

Phase

Phase Study_Count
Phase 2 340
Phase 3 297
Phase 1 248
Phase 4 192
N/A 168
Phase 1/Phase 2 45
Phase 2/Phase 3 32
Early Phase 1 5

Number of Arms

Number_of_Arms Count_of_Studies
1 341
2 430
3 178
4 100
5 42
6 38
7 23
8 11
9 9
10 9
11 3
12 5
13 1
14 5
15 2
18 1
20 1
22 3
27 1
NA 124

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 1 2.000 2.00000 6.00000 2.0000 10.0000 9.0000 6.00
1st Qu. 25 52.250 20.00000 24.00000 37.0000 45.0000 102.0000 30.00
Median 26 159.000 31.50000 41.00000 70.0000 141.0000 199.5000 80.00
Mean 631 1503.295 39.39516 62.60465 126.8571 299.6129 334.6588 1486.22
3rd Qu. 52 424.250 49.00000 72.50000 161.5000 398.5000 419.2500 198.50
Max. 3051 50000.000 177.00000 548.00000 1030.0000 1400.0000 5000.0000 221855.00

Trial Group Type

group_type Group_Count
Experimental 2519
Active Comparator 452
Placebo Comparator 180
NA 124
Other 109
No Intervention 69
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 779
Single Group Assignment 444
Crossover Assignment 60
NA 18
Sequential Assignment 14
Factorial Assignment 12

Primary Purpose

primary_purpose Study_Count
Treatment 1086
Prevention 61
NA 54
Diagnostic 30
Health Services Research 25
Other 25
Basic Science 17
Screening 17
Supportive Care 12

Observational Studies

Studies by Country

Country Study_Count
United States 74
NA 66
France 16
Japan 10
Spain 10
Australia 9
Egypt 9
Canada 8
Taiwan 8
Brazil 7
Germany 7
Netherlands 7
United States|Puerto Rico 7
China 6
Italy 6
Korea, Republic of 6
United Kingdom 5
Austria 4
India 4
Russian Federation 4
Israel 3
Mexico 3
Switzerland 3
Turkey 3
Belgium 2
Cambodia 2
Denmark 2
Hong Kong 2
Singapore 2
Thailand 2
Australia|United States|Austria|Belgium|Canada|Czechia|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
Belgium|France|Germany|Netherlands|Switzerland|United Kingdom 1
Belgium|Georgia|Nigeria 1
Bulgaria 1
Cambodia|Georgia 1
China|Japan 1
Colombia 1
Czech Republic 1
France|Austria|Belgium|Greece|Israel|Italy|Poland|Portugal|Switzerland 1
France|Hungary|Austria|Brazil|Canada|Croatia|Macedonia, The Former Yugoslav Republic of|Mexico|Morocco|Poland|Romania|Serbia|Slovenia|Sweden 1
Georgia 1
Greece 1
Greece|Belgium|Egypt|Estonia|France|Germany|Hungary|Ireland|Italy|Kuwait|Lebanon|Macedonia, The Former Yugoslav Republic of|Morocco|Oman|Pakistan|Portugal|Qatar|Romania|Saudi Arabia|Serbia|Sweden|Switzerland|Syrian Arab Republic|Taiwan|Turkey|United Arab Emirates|United Kingdom 1
Hungary 1
Iceland 1
Italy|Belgium|Ireland|United Kingdom 1
Kenya 1
Korea, Republic of|Russian Federation 1
Korea, Republic of|Taiwan 1
Lebanon|Albania|Algeria|Bahrain|Belgium|Bosnia and Herzegovina|Brazil|Egypt|Greece|Hungary|India|Iran, Islamic Republic of|Italy|Korea, Republic of|Kuwait|Macedonia, The Former Yugoslav Republic of|Morocco|Pakistan|Poland|Portugal|Qatar|Romania|Serbia|Slovakia|United Arab Emirates 1
Myanmar 1
Norway 1
Poland 1
Puerto Rico 1
Saudi Arabia 1
Senegal 1
Slovenia 1
Sweden 1
Ukraine 1
United States|Argentina|Australia|Austria|Belgium|Canada|Finland|France|Germany|Greece|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Puerto Rico|Romania|Spain 1
United States|Argentina|Australia|Brazil|Canada|Denmark|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Mexico|Poland|Puerto Rico|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Canada 1
United States|Canada|France|Germany|Puerto Rico 1
United States|Canada|Germany|Puerto Rico 1
United States|Egypt 1
United States|France|Germany|Italy|Spain 1
United States|United Kingdom 1
Vietnam 1

Sites per Study

Site_count Study_Count
1 229
2 18
3 13
4 9
5 3
6 5
7 2
8 1
9 5
10 3
11 2
12 1
14 1
17 1
18 2
19 2
21 1
26 2
27 1
30 1
33 1
34 1
37 2
39 1
41 1
43 1
45 2
46 1
53 1
57 1
58 1
59 1
60 1
61 1
66 1
70 1
73 1
74 1
75 1
101 1
104 1
106 1
125 1
156 1
161 1
170 1
261 1
266 1
272 1
323 1
325 1
388 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 79.750
Median 250.000
Mean 4153.994
3rd Qu 792.500
Max 815000.000

Observation Model

observational_model Study_Count
Cohort 212
Case-Only 37
NA 33
Case Control 17
Other 16
Case-Control 14
Ecologic or Community 6
Defined Population, Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 233
Retrospective 43
Cross-Sectional 26
NA 17
Other 16
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
Spain 5
United States 3
Egypt 2
Japan 2
Argentina 1
Austria 1
China 1
Germany 1
Italy 1
Korea, Republic of 1
NA 1
Portugal|Argentina|Austria|Belarus|Belgium|Bosnia and Herzegovina|Croatia|Czechia|Denmark|Estonia|Finland|France|Georgia|Germany|Greece|Hungary|Iceland|Ireland|Israel|Italy|Latvia|Lithuania|Luxembourg|Netherlands|Norway|Poland|Romania|Russian Federation|Serbia|Slovakia|Slovenia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United Kingdom 1
United States|Australia|Belgium|Germany|Italy|New Zealand|Russian Federation|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Spain|United Kingdom 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 18
13 1
18 1
48 2
110 1
138 1

Enrollment Metrics

Measure Registries
Min 8.000
1st Qu 273.000
Median 700.000
Mean 1874.458
3rd Qu 1631.750
Max 23000.000

Registry Model

observational_model Study_Count
Cohort 18
Case-Control 2
Case-Only 2
Other 2

Time Perspective

time_perspective Study_Count
Prospective 19
Cross-Sectional 2
Other 2
NA 1

Follow-up

target_duration Study_Count
12 Months 3
24 Weeks 3
5 Years 3
1 Day 2
3 Years 2
6 Years 2
1 Year 1
10 Years 1
144 Weeks 1
2 Years 1
3 Months 1
30 Years 1
36 Months 1
48 Weeks 1
8 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04139941 Evaluation Study of HCV RDTs in Fresh Samples https://ClinicalTrials.gov/show/NCT04139941 Completed Foundation for Innovative New Diagnostics, Switzerland 2019-12-31
NCT01514890 French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin https://ClinicalTrials.gov/show/NCT01514890 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2014-03-31
NCT03366610 Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens https://ClinicalTrials.gov/show/NCT03366610 Completed Bristol-Myers Squibb 2019-04-30
NCT03343925 Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings https://ClinicalTrials.gov/show/NCT03343925 Recruiting Kirby Institute 2021-07-01
NCT03342261 Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia https://ClinicalTrials.gov/show/NCT03342261 Completed Hospices Civils de Lyon 2017-11-01
NCT03341871 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 https://ClinicalTrials.gov/show/NCT03341871 Active, not recruiting AbbVie 2020-12-31
NCT03318887 Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA https://ClinicalTrials.gov/show/NCT03318887 Completed Hospices Civils de Lyon 2014-09-30
NCT03316313 Hepatitis C Screening in the Primary Care Setting https://ClinicalTrials.gov/show/NCT03316313 Completed New York Institute of Technology 2016-10-31
NCT03313154 Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related https://ClinicalTrials.gov/show/NCT03313154 Completed Azienda Ospedaliero Universitaria di Cagliari 2018-07-31
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 https://ClinicalTrials.gov/show/NCT03303599 Completed AbbVie 2020-01-24
NCT03290755 Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux https://ClinicalTrials.gov/show/NCT03290755 Completed University Hospital, Bordeaux 2018-03-13
NCT03276039 Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus https://ClinicalTrials.gov/show/NCT03276039 Completed Ain Shams University 2016-04-15
NCT03254121 Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response https://ClinicalTrials.gov/show/NCT03254121 Recruiting Karolinska Institutet 2021-01-01
NCT03248622 Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT03248622 Completed National Institutes of Health Clinical Center (CC) 2019-05-28
NCT03246048 Long Term Follow-up of Hepatitis C Cured Patients https://ClinicalTrials.gov/show/NCT03246048 Active, not recruiting Hospital Universitari Vall d’Hebron Research Institute 2021-01-31
NCT03245931 Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1 https://ClinicalTrials.gov/show/NCT03245931 Completed TriHealth Inc. 2019-08-26
NCT03221309 Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior https://ClinicalTrials.gov/show/NCT03221309 Enrolling by invitation University of Maryland, Baltimore 2021-01-31
NCT03205618 A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar https://ClinicalTrials.gov/show/NCT03205618 Completed Bristol-Myers Squibb 2017-06-27
NCT03201718 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs https://ClinicalTrials.gov/show/NCT03201718 Completed AbbVie 2019-10-11
NCT03200379 Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan https://ClinicalTrials.gov/show/NCT03200379 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2037-06-15
NCT03200171 Effect of DAAs on Behavior of HCC in HCV Patients https://ClinicalTrials.gov/show/NCT03200171 Recruiting Al-Azhar University 2019-08-31
NCT03197155 Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence https://ClinicalTrials.gov/show/NCT03197155 Completed Hospices Civils de Lyon 2017-01-31
NCT03186235 T Regulatory Cells in Hepatitis c Infected Patients https://ClinicalTrials.gov/show/NCT03186235 Completed Assiut University 2019-08-01
NCT03181074 Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults https://ClinicalTrials.gov/show/NCT03181074 Completed Bristol-Myers Squibb 2019-08-19
NCT03149289 Hepatitis C Virus Infection in Patients With Hemoglobinopathies https://ClinicalTrials.gov/show/NCT03149289 Completed Società Italiana Talassemie ed Emoglobinopatie 2016-03-01
NCT03145844 Direct Acting Agents in Hepatitis C Patients https://ClinicalTrials.gov/show/NCT03145844 Completed Viral Hepatitis Society 2018-12-31
NCT03145623 Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT03145623 Completed University Hospital, Toulouse 2017-12-31
NCT03144440 Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel https://ClinicalTrials.gov/show/NCT03144440 Active, not recruiting Carmel Medical Center 2020-01-01
NCT03122132 Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks https://ClinicalTrials.gov/show/NCT03122132 Completed Hepa C 2018-01-01
NCT03109457 Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03109457 Completed Cairo University 2018-02-07
NCT03088995 Pilot Study of HIV and Hepatitis B and C Screening in Surgery https://ClinicalTrials.gov/show/NCT03088995 Completed Centre de Recherches et d’Etude sur la Pathologie Tropicale et le Sida 2017-09-01
NCT03088917 ‘Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat’ https://ClinicalTrials.gov/show/NCT03088917 Completed Radboud University 2019-12-01
NCT03071133 Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy https://ClinicalTrials.gov/show/NCT03071133 Active, not recruiting Bristol-Myers Squibb 2019-11-14
NCT03063723 Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs https://ClinicalTrials.gov/show/NCT03063723 Completed Third Affiliated Hospital, Sun Yat-Sen University 2016-12-01
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation https://ClinicalTrials.gov/show/NCT03053180 Completed AbbVie 2017-12-18
NCT03038763 Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers https://ClinicalTrials.gov/show/NCT03038763 Completed University of Pennsylvania 2019-06-30
NCT03042520 Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment https://ClinicalTrials.gov/show/NCT03042520 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2022-09-30
NCT03000023 Anticipated and Perceived Benefits Following Hepatitis C Treatment https://ClinicalTrials.gov/show/NCT03000023 Completed University of North Carolina, Chapel Hill 2018-07-31
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) https://ClinicalTrials.gov/show/NCT03002818 Completed AbbVie 2018-04-25
NCT02995252 The HOPE Study: Characterizing Patients With Hepatitis B and C https://ClinicalTrials.gov/show/NCT02995252 Recruiting University of Maryland, Baltimore 2020-01-31
NCT02992184 PoC-HCV Genedrive Viral Detection Assay Validation Study https://ClinicalTrials.gov/show/NCT02992184 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2016-12-31
NCT02982993 Hepatitis C Infection in World Trade Center Responders https://ClinicalTrials.gov/show/NCT02982993 Completed Icahn School of Medicine at Mount Sinai 2018-07-12
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2 https://ClinicalTrials.gov/show/NCT02945228 Completed AbbVie 2019-07-26
NCT02943330 Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life https://ClinicalTrials.gov/show/NCT02943330 Completed Chang Gung Memorial Hospital 2010-10-31
NCT02907996 Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea https://ClinicalTrials.gov/show/NCT02907996 Recruiting Gilead Sciences 2021-09-30
NCT02904252 The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital https://ClinicalTrials.gov/show/NCT02904252 Completed Mahidol University 2016-10-31
NCT02877199 Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy https://ClinicalTrials.gov/show/NCT02877199 Completed Hospices Civils de Lyon 2015-04-30
NCT02881034 Ribavirin Bioavailability After Telaprevir Exposure https://ClinicalTrials.gov/show/NCT02881034 Completed Hospices Civils de Lyon 2015-02-28
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia https://ClinicalTrials.gov/show/NCT02851069 Completed AbbVie 2018-08-30
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02817594 Completed AbbVie 2018-03-07
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania https://ClinicalTrials.gov/show/NCT02807402 Completed AbbVie 2017-08-04
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02803138 Completed AbbVie 2018-10-21
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study https://ClinicalTrials.gov/show/NCT02798315 Completed AbbVie 2017-06-12
NCT02788682 Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy https://ClinicalTrials.gov/show/NCT02788682 Completed Cairo University 2015-07-31
NCT02786758 Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals https://ClinicalTrials.gov/show/NCT02786758 Completed Macfarlane Burnet Institute for Medical Research and Public Health Ltd 2019-07-31
NCT02783976 Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice https://ClinicalTrials.gov/show/NCT02783976 Completed Gilead Sciences 2018-06-20
NCT02785835 Hepatocellular Carcinoma in HIV-infected Patients https://ClinicalTrials.gov/show/NCT02785835 Recruiting Hospital Universitario de Valme 2016-12-31
NCT02773394 Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil https://ClinicalTrials.gov/show/NCT02773394 Completed Janssen-Cilag Ltd. 2016-11-30
NCT02758509 Impact of Antiviral Therapy on Gastroesophageal Varices. https://ClinicalTrials.gov/show/NCT02758509 Completed Parc de Salut Mar 2017-06-15
NCT02749864 Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP) https://ClinicalTrials.gov/show/NCT02749864 Completed Instituto de Investigación Marqués de Valdecilla 2017-04-01
NCT02726022 A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels https://ClinicalTrials.gov/show/NCT02726022 Completed Hoffmann-La Roche 2011-07-31
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02725866 Completed AbbVie 2017-10-31
NCT02718573 Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood https://ClinicalTrials.gov/show/NCT02718573 Completed Icahn School of Medicine at Mount Sinai 2017-12-11
NCT02714712 SR-BI and Antiviral Treatment Response in HCV https://ClinicalTrials.gov/show/NCT02714712 Completed Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 2016-07-31
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT02669940 Completed AbbVie 2017-07-04
NCT02650024 Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes https://ClinicalTrials.gov/show/NCT02650024 Recruiting University of California, San Diego 2020-07-31
NCT02647879 Treatment as Prevention for Hepatitis C in Iceland https://ClinicalTrials.gov/show/NCT02647879 Recruiting Landspitali University Hospital 2020-12-31
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02640547 Completed AbbVie 2017-03-29
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary https://ClinicalTrials.gov/show/NCT02636608 Completed AbbVie 2018-05-23
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 https://ClinicalTrials.gov/show/NCT02629172 Completed AbbVie 2019-02-28
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France https://ClinicalTrials.gov/show/NCT02618928 Completed AbbVie 2018-03-29
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) https://ClinicalTrials.gov/show/NCT02615145 Completed AbbVie 2018-03-26
NCT02601820 The Patient-Reported Outcomes Project of HCV-TARGET https://ClinicalTrials.gov/show/NCT02601820 Completed University of North Carolina, Chapel Hill 2018-07-31
NCT02597790 A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects https://ClinicalTrials.gov/show/NCT02597790 Completed University of California, Los Angeles 2019-01-31
NCT02597270 An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection https://ClinicalTrials.gov/show/NCT02597270 Completed Janssen-Cilag Ltd. 2016-11-30
NCT02591277 Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02591277 Completed Gilead Sciences 2017-11-01
NCT02592057 Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India https://ClinicalTrials.gov/show/NCT02592057 Completed Gilead Sciences 2017-11-30
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland https://ClinicalTrials.gov/show/NCT02582671 Completed AbbVie 2017-11-29
NCT02583243 Project BEST: Buprenorphine Entry Into Substance Abuse Treatment https://ClinicalTrials.gov/show/NCT02583243 Completed Yale University 2008-08-31
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada https://ClinicalTrials.gov/show/NCT02581189 Completed AbbVie 2017-12-20
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) https://ClinicalTrials.gov/show/NCT02582658 Completed AbbVie 2017-01-12
NCT00004850 Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT00004850 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT01350648 Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection https://ClinicalTrials.gov/show/NCT01350648 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02562742 Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02562742 Completed Gilead Sciences 2017-06-12
NCT02556307 A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients https://ClinicalTrials.gov/show/NCT02556307 Completed Hoffmann-La Roche 2014-07-31
NCT02557646 An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02557646 Completed Hoffmann-La Roche 2014-03-31
NCT02545400 Quantification of Side Effects During Hepatitis C Therapy https://ClinicalTrials.gov/show/NCT02545400 Completed Medical University of Graz 2014-06-30
NCT02545335 Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02545335 Active, not recruiting Medical University of Graz 2020-12-31
NCT02537379 Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02537379 Completed Gilead Sciences 2017-06-05
NCT02532907 Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs https://ClinicalTrials.gov/show/NCT02532907 Completed University of Colorado, Denver 2018-07-10
NCT02528461 Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02528461 Completed University of Aarhus 2019-01-31
NCT02531269 Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period https://ClinicalTrials.gov/show/NCT02531269 Completed Bristol-Myers Squibb 2016-02-29
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02526641 Active, not recruiting University of Aarhus 2019-03-31
NCT02508090 Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin https://ClinicalTrials.gov/show/NCT02508090 Completed Hoffmann-La Roche 2017-01-13
NCT02452814 Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection https://ClinicalTrials.gov/show/NCT02452814 Completed Hoffmann-La Roche 2017-05-03
NCT02439918 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa https://ClinicalTrials.gov/show/NCT02439918 Completed Université de Sherbrooke 2012-08-31
NCT02427204 Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality https://ClinicalTrials.gov/show/NCT02427204 Completed Icahn School of Medicine at Mount Sinai 2018-01-18
NCT02366286 Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants https://ClinicalTrials.gov/show/NCT02366286 Active, not recruiting Mayo Clinic 2022-12-31
NCT02361541 Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia https://ClinicalTrials.gov/show/NCT02361541 Completed Institute of Tropical Medicine, Belgium 2016-04-30
NCT02333292 Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions https://ClinicalTrials.gov/show/NCT02333292 Recruiting Valme University Hospital 2020-11-30
NCT02275221 Immune Response in Patients With Hepatitis B and C Infection https://ClinicalTrials.gov/show/NCT02275221 Recruiting Basildon and Thurrock University Hospitals NHS Foundation Trust 2019-12-31
NCT02196064 Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the “The HEPAVIR HEPATIC SAFETY Cohort.” https://ClinicalTrials.gov/show/NCT02196064 Completed Andalusian Network for Design and Translation of Advanced Therapies 2015-07-31
NCT02106156 Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) https://ClinicalTrials.gov/show/NCT02106156 Completed Hoffmann-La Roche 2013-09-30
NCT02103699 A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir https://ClinicalTrials.gov/show/NCT02103699 Completed Janssen Scientific Affairs, LLC 2015-11-30
NCT02102451 Control and Elimination Within Australia of Hepatitis C From People Living With HIV https://ClinicalTrials.gov/show/NCT02102451 Active, not recruiting Kirby Institute 2020-12-31
NCT02083367 Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome https://ClinicalTrials.gov/show/NCT02083367 Completed OSF Healthcare System 2014-10-31
NCT02068963 Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing https://ClinicalTrials.gov/show/NCT02068963 Completed Hologic, Inc. 2015-04-30
NCT02065999 Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT02065999 Recruiting Kirby Institute 2022-04-30
NCT01310205 Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV https://ClinicalTrials.gov/show/NCT01310205 Completed SciClone Pharmaceuticals 2012-03-31
NCT01296529 Study on Immunopathogenesis in HIV and Hepatitis C Coinfection https://ClinicalTrials.gov/show/NCT01296529 Completed Rush University Medical Center 2011-12-31
NCT01293279 HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China https://ClinicalTrials.gov/show/NCT01293279 Completed Peking University People’s Hospital 2011-06-30
NCT01280825 The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing https://ClinicalTrials.gov/show/NCT01280825 Recruiting University of Chicago 2020-11-14
NCT01280656 A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION) https://ClinicalTrials.gov/show/NCT01280656 Completed Hoffmann-La Roche 2012-11-30
NCT01272479 Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01272479 Completed Istanbul University 2010-03-31
NCT02057003 Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients https://ClinicalTrials.gov/show/NCT02057003 Recruiting Valme University Hospital 2020-12-31
NCT02044523 Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound https://ClinicalTrials.gov/show/NCT02044523 Completed Centre hospitalier de l’Université de Montréal (CHUM) 2018-06-30
NCT04202081 Voices From the Black Community: Hepatitis C Research Participation https://ClinicalTrials.gov/show/NCT04202081 Completed University of North Carolina, Chapel Hill 2020-05-15
NCT02951364 Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea https://ClinicalTrials.gov/show/NCT02951364 Recruiting Gilead Sciences 2021-10-31
NCT02011932 Prospective Observational Study of Disease Progression in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02011932 Active, not recruiting Beijing YouAn Hospital 2011-06-30
NCT02006823 Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02006823 Completed Duke University 2014-07-31
NCT02000063 Australian Trial in Acute Hepatitis C Recall Study https://ClinicalTrials.gov/show/NCT02000063 Completed Kirby Institute 2014-03-31
NCT01988753 Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases https://ClinicalTrials.gov/show/NCT01988753 Completed Baylor College of Medicine 2016-06-30
NCT01980290 Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01980290 Completed Janssen Pharmaceutica N.V., Belgium 2015-02-28
NCT01953458 Therapeutic Option for Hepatitis B and C: a French Cohort https://ClinicalTrials.gov/show/NCT01953458 Recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2022-08-31
NCT01945008 Observational Study in HCV Chronic Infection https://ClinicalTrials.gov/show/NCT01945008 Completed Istituto Superiore di Sanità 2015-11-30
NCT01921400 The Pathogenesis of Hepatitis C Virus Vertical Transmission https://ClinicalTrials.gov/show/NCT01921400 Completed University of North Carolina, Chapel Hill 2017-12-31
NCT01884402 Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 https://ClinicalTrials.gov/show/NCT01884402 Completed Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2014-05-31
NCT01850745 Multidisciplinary Support Program in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01850745 Completed Parc de Salut Mar 2009-01-31
NCT01772121 Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India https://ClinicalTrials.gov/show/NCT01772121 Completed Gilead Sciences 2012-10-31
NCT01771653 Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01771653 Completed Southern Illinois University 2015-07-31
NCT01750216 An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT01750216 Completed Hoffmann-La Roche 2015-01-31
NCT01726400 In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia https://ClinicalTrials.gov/show/NCT01726400 Completed Fremantle Hospital and Health Service 2014-01-31
NCT01715779 Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies https://ClinicalTrials.gov/show/NCT01715779 Completed Novartis 2015-06-30
NCT01711164 The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis https://ClinicalTrials.gov/show/NCT01711164 Completed University Health Network, Toronto 2016-05-31
NCT01705717 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01705717 Completed Hoffmann-La Roche 2012-05-01
NCT01679834 An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01679834 Completed Hoffmann-La Roche 2017-07-14
NCT01671046 An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01671046 Completed Hoffmann-La Roche 2015-12-31
NCT01667081 Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) https://ClinicalTrials.gov/show/NCT01667081 Enrolling by invitation Merck Sharp & Dohme Corp. 2021-05-24
NCT01659567 A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C https://ClinicalTrials.gov/show/NCT01659567 Completed Hoffmann-La Roche 2015-10-20
NCT01644903 Proteogenomic Monitoring and Assessment of Liver Transplant Recipients https://ClinicalTrials.gov/show/NCT01644903 Recruiting Northwestern University 2024-12-31
NCT01641094 Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms https://ClinicalTrials.gov/show/NCT01641094 Completed Foundation for Liver Research 2014-06-30
NCT01634919 Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin https://ClinicalTrials.gov/show/NCT01634919 Completed Seoul National University Boramae Hospital 2017-02-17
NCT01619475 Adult-to-Adult Living Donor Transplant Cohort Study https://ClinicalTrials.gov/show/NCT01619475 Completed Arbor Research Collaborative for Health 2014-08-31
NCT01609049 An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis https://ClinicalTrials.gov/show/NCT01609049 Completed Hoffmann-La Roche 2015-06-22
NCT01604291 An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01604291 Completed Hoffmann-La Roche 2016-02-10
NCT01577069 Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir https://ClinicalTrials.gov/show/NCT01577069 Completed Association HGE CHU Bordeaux Sud 2013-01-31
NCT03348059 Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy https://ClinicalTrials.gov/show/NCT03348059 Completed Hospices Civils de Lyon 2016-11-30
NCT01544582 Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518) https://ClinicalTrials.gov/show/NCT01544582 Completed Merck Sharp & Dohme Corp. 2015-07-31
NCT01534728 Identification of Hepatitis C Virus (HCV) Specific T Cells https://ClinicalTrials.gov/show/NCT01534728 Completed Institut National de la Santé Et de la Recherche Médicale, France 2014-03-31
NCT01525810 Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial https://ClinicalTrials.gov/show/NCT01525810 Completed Bristol-Myers Squibb 2014-11-30
NCT01517529 Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations https://ClinicalTrials.gov/show/NCT01517529 Completed University of Cincinnati 2014-07-31
NCT01508130 An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT01508130 Completed Hoffmann-La Roche 2014-03-31
NCT01492504 Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial https://ClinicalTrials.gov/show/NCT01492504 Completed Bristol-Myers Squibb 2018-03-16
NCT01474811 HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network https://ClinicalTrials.gov/show/NCT01474811 Recruiting University of North Carolina, Chapel Hill 2020-12-31
NCT01464008 The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01464008 Completed Beijing Ditan Hospital 2011-05-31
NCT01458080 WEUSKOP5410: Observational Study in ENABLE Clinical Trials https://ClinicalTrials.gov/show/NCT01458080 Completed GlaxoSmithKline 2013-11-30
NCT01457768 A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response https://ClinicalTrials.gov/show/NCT01457768 Completed Gilead Sciences 2018-04-09
NCT01457755 Gilead Sustained Virologic Response (SVR) Registry https://ClinicalTrials.gov/show/NCT01457755 Completed Gilead Sciences 2017-03-28
NCT01453244 Pharmacogenomic Research in Korean Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT01453244 Completed Inje University 2013-03-31
NCT01448915 Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs) https://ClinicalTrials.gov/show/NCT01448915 Active, not recruiting Johns Hopkins University 2021-04-30
NCT01447680 Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing https://ClinicalTrials.gov/show/NCT01447680 Completed G & W Laboratories Inc. 2012-12-31
NCT01447446 An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01447446 Completed Hoffmann-La Roche 2015-07-31
NCT01429155 Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B https://ClinicalTrials.gov/show/NCT01429155 Completed Henry Ford Health System 2013-01-31
NCT01428700 Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C https://ClinicalTrials.gov/show/NCT01428700 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2013-01-31
NCT01423643 HCV/HIV Coinfection: Antiviral Therapy and Fibrosis https://ClinicalTrials.gov/show/NCT01423643 Completed Johns Hopkins University 2015-10-31
NCT01416610 An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy https://ClinicalTrials.gov/show/NCT01416610 Completed Hoffmann-La Roche 2014-10-31
NCT01413490 Hepatitis C Rimantadine and Antiviral Combination Therapy https://ClinicalTrials.gov/show/NCT01413490 Completed The Leeds Teaching Hospitals NHS Trust 2015-03-31
NCT01402583 Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01402583 Completed University of Modena and Reggio Emilia 2011-08-31
NCT01405183 Association Between Hepatitis C Infection and Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01405183 Completed Henry Ford Health System 2013-08-31
NCT01403181 Effect of Boceprevir on HCV-specific T Cell Responses https://ClinicalTrials.gov/show/NCT01403181 Completed Azienda Ospedaliero-Universitaria di Parma 2013-10-31
NCT01392742 An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin https://ClinicalTrials.gov/show/NCT01392742 Completed Hoffmann-La Roche 2014-07-31
NCT01355107 Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease https://ClinicalTrials.gov/show/NCT01355107 Completed University Hospital Freiburg 2011-12-31
NCT01344889 An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C) https://ClinicalTrials.gov/show/NCT01344889 Completed Hoffmann-La Roche 2013-06-30
NCT01342003 HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b https://ClinicalTrials.gov/show/NCT01342003 Completed Azienda Ospedaliera San Camillo Forlanini 2010-07-31
NCT01335230 The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients https://ClinicalTrials.gov/show/NCT01335230 Completed University of Cincinnati 2013-01-31
NCT04389268 P300 in Early Cognitive Impairment in Hepatitis C Virus https://ClinicalTrials.gov/show/NCT04389268 Completed Mansoura University Hospital 2019-01-01
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis https://ClinicalTrials.gov/show/NCT04352309 Recruiting AbbVie 2021-04-20
NCT04330508 Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial https://ClinicalTrials.gov/show/NCT04330508 Recruiting Postgraduate Institute of Medical Education and Research 2020-10-31
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus https://ClinicalTrials.gov/show/NCT04214028 Recruiting AbbVie 2024-12-30
NCT04208035 Hepatitis C Elimination in the Netherlands https://ClinicalTrials.gov/show/NCT04208035 Recruiting Radboud University 2021-01-01
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation https://ClinicalTrials.gov/show/NCT04189627 Recruiting AbbVie 2021-03-01
NCT04159545 Future Destinations: Journeys Towards Citizenship https://ClinicalTrials.gov/show/NCT04159545 Recruiting University of Dundee 2022-04-30
NCT04159246 Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT04159246 Active, not recruiting Cairo University 2019-11-30
NCT04094272 Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT04094272 Completed Kantonsspital Olten 2019-05-01
NCT04090164 Association of Hepatitis C Virus With Breast Cancer https://ClinicalTrials.gov/show/NCT04090164 Active, not recruiting Mansoura University 2020-06-30
NCT04071353 Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04071353 Recruiting Beijing Ditan Hospital 2020-08-01
NCT04063839 HCV Treatment in a Low-threshold Clinic https://ClinicalTrials.gov/show/NCT04063839 Recruiting University Hospital, Akershus 2019-10-31
NCT00222859 Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting https://ClinicalTrials.gov/show/NCT00222859 Completed University of Pittsburgh 2011-12-31
NCT04057001 Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study https://ClinicalTrials.gov/show/NCT04057001 Recruiting Yale University 2020-06-30
NCT04047680 eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs https://ClinicalTrials.gov/show/NCT04047680 Completed National Taiwan University Hospital 2018-12-31
NCT04044586 HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST) https://ClinicalTrials.gov/show/NCT04044586 Active, not recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2019-09-30
NCT04038320 Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine https://ClinicalTrials.gov/show/NCT04038320 Completed Right to Care 2019-03-30
NCT04033887 Evaluation Study of RDTs Detecting Antibodies Against HCV https://ClinicalTrials.gov/show/NCT04033887 Completed Foundation for Innovative New Diagnostics, Switzerland 2019-03-15
NCT03993925 Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong https://ClinicalTrials.gov/show/NCT03993925 Recruiting The University of Hong Kong 2020-09-30
NCT03980301 Screening Hepatitis Positive Women for Congenital Anomalies https://ClinicalTrials.gov/show/NCT03980301 Recruiting Aljazeera Hospital 2020-06-15
NCT03908294 Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents https://ClinicalTrials.gov/show/NCT03908294 Completed Johann Wolfgang Goethe University Hospital 2020-01-01
NCT03923595 Puglia HCV Micro-elimination Program https://ClinicalTrials.gov/show/NCT03923595 Recruiting Casa Sollievo della Sofferenza IRCCS 2020-08-21
NCT03902366 HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function https://ClinicalTrials.gov/show/NCT03902366 Recruiting VA Office of Research and Development 2023-10-31
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT03868163 Active, not recruiting AbbVie 2020-08-15
NCT03880682 Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT03880682 Completed Istanbul University 2019-06-15
NCT03839979 HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt https://ClinicalTrials.gov/show/NCT03839979 Completed Cairo University 2018-12-31
NCT03803410 Surveillance of HCV in Uremics and Linking to Medical Care https://ClinicalTrials.gov/show/NCT03803410 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2021-12-31
NCT03776760 Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination https://ClinicalTrials.gov/show/NCT03776760 Recruiting Kirby Institute 2022-02-28
NCT03740906 Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting https://ClinicalTrials.gov/show/NCT03740906 Recruiting Kirby Institute 2021-01-31
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs https://ClinicalTrials.gov/show/NCT03740230 Recruiting AbbVie 2022-09-30
NCT03707080 Direct Acting Antiviral-Post Authorization Safety Study https://ClinicalTrials.gov/show/NCT03707080 Active, not recruiting Target PharmaSolutions, Inc. 2020-12-31
NCT03702998 Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population https://ClinicalTrials.gov/show/NCT03702998 Recruiting Chinese University of Hong Kong 2020-07-31
NCT03697135 Ask a Friend to Take a Test for Hepatitis C Infection https://ClinicalTrials.gov/show/NCT03697135 Enrolling by invitation NHS Tayside 2019-12-30
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis https://ClinicalTrials.gov/show/NCT03693586 Recruiting Hospital General de Mexico 2020-05-01
NCT03579576 Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar https://ClinicalTrials.gov/show/NCT03579576 Completed Right to Care 2019-03-30
NCT03570112 Transmission of Chronic Hepatitis C in Pregnancy https://ClinicalTrials.gov/show/NCT03570112 Recruiting The Christ Hospital 2020-06-30
NCT03566563 Epidemiology of Chronic Hepatitis C and Disease Modelling https://ClinicalTrials.gov/show/NCT03566563 Recruiting Changi General Hospital 2019-02-18
NCT03564639 Examining Hepatitis C Reinfection Rates in Kenya https://ClinicalTrials.gov/show/NCT03564639 Enrolling by invitation Yale University 2020-11-30
NCT03551002 Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego https://ClinicalTrials.gov/show/NCT03551002 Recruiting University of California, San Diego 2020-12-31
NCT03526939 DRug Use and Infections in Hai Phong ViEtnam Among Persons Who Inject Drugs https://ClinicalTrials.gov/show/NCT03526939 Recruiting New York University 2020-10-17
NCT03520660 People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents https://ClinicalTrials.gov/show/NCT03520660 Recruiting National Institutes of Health Clinical Center (CC) 2032-12-31
NCT03513796 Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside https://ClinicalTrials.gov/show/NCT03513796 Active, not recruiting NHS Tayside 2018-12-31
NCT03510637 “Real Life” Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt https://ClinicalTrials.gov/show/NCT03510637 Recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-08-31
NCT03508115 Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents https://ClinicalTrials.gov/show/NCT03508115 Completed Corporacion Parc Tauli 2017-09-06
NCT03500562 Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) https://ClinicalTrials.gov/show/NCT03500562 Recruiting Bristol-Myers Squibb 2021-12-31
NCT03459768 Cohort Study on People Who Inject Drugs in Senegal https://ClinicalTrials.gov/show/NCT03459768 Active, not recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-02-29
NCT03423641 An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT03423641 Completed Kaiser Permanente 2017-12-31
NCT03413696 Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients https://ClinicalTrials.gov/show/NCT03413696 Enrolling by invitation University of California, San Diego 2019-12-31
NCT03415009 Prevalence of IL28B Polymorphism in Hepatitis C Patients https://ClinicalTrials.gov/show/NCT03415009 Completed Changi General Hospital 2016-06-30
NCT01208311 Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound https://ClinicalTrials.gov/show/NCT01208311 Completed Northwell Health 2016-12-31
NCT01206933 The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System https://ClinicalTrials.gov/show/NCT01206933 Completed George Washington University 2015-06-30
NCT01200225 An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) https://ClinicalTrials.gov/show/NCT01200225 Completed Hoffmann-La Roche 2013-06-30
NCT01159613 Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection? https://ClinicalTrials.gov/show/NCT01159613 Completed Ziv Hospital 2008-10-31
NCT01112033 Biliverdin Reductase A in Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT01112033 Completed Charles University, Czech Republic 2013-03-31
NCT01098097 Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) https://ClinicalTrials.gov/show/NCT01098097 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT01070550 PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) https://ClinicalTrials.gov/show/NCT01070550 Completed Hoffmann-La Roche 2011-07-31
NCT01066819 PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b https://ClinicalTrials.gov/show/NCT01066819 Completed Hoffmann-La Roche 2011-08-31
NCT01066793 PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b https://ClinicalTrials.gov/show/NCT01066793 Completed Hoffmann-La Roche 2011-03-31
NCT01054742 Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) https://ClinicalTrials.gov/show/NCT01054742 Completed Merck Sharp & Dohme Corp. 2011-06-30
NCT01033045 Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure https://ClinicalTrials.gov/show/NCT01033045 Completed Fundacion IMIM 2013-07-31
NCT00998621 ADHEPTA Study: Adherence Questionnaire in Hepatitis C https://ClinicalTrials.gov/show/NCT00998621 Completed Fundacion IMIM 2010-09-30
NCT00979979 Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test https://ClinicalTrials.gov/show/NCT00979979 Completed National Taiwan University Hospital 2013-10-31
NCT00946010 Investigation of Hepatitis B and Hepatitis C in Taiwan https://ClinicalTrials.gov/show/NCT00946010 Completed National Taiwan University Hospital 2010-08-31
NCT00916474 Virology Follow up Study in Subjects Previously Treated With Telaprevir https://ClinicalTrials.gov/show/NCT00916474 Completed Vertex Pharmaceuticals Incorporated 2013-12-31
NCT00893308 Metabolic Viral Host Properties https://ClinicalTrials.gov/show/NCT00893308 Completed Hadassah Medical Organization NA
NCT00863109 Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) https://ClinicalTrials.gov/show/NCT00863109 Completed Merck Sharp & Dohme Corp. 2013-05-31
NCT04242433 HCV RAS Testing in Public Health Programs https://ClinicalTrials.gov/show/NCT04242433 Recruiting Postgraduate Institute of Medical Education and Research 2021-01-31
NCT00825877 Long-term Follow-up of HALT-C Sustained Virological Responders https://ClinicalTrials.gov/show/NCT00825877 Completed National Institutes of Health Clinical Center (CC) NA
NCT04366973 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers https://ClinicalTrials.gov/show/NCT04366973 Recruiting AbbVie 2022-09-30
NCT04048850 Zepatier in Patients With Substance Use https://ClinicalTrials.gov/show/NCT04048850 Enrolling by invitation University of Illinois at Chicago 2020-08-01
NCT04036760 Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails https://ClinicalTrials.gov/show/NCT04036760 Completed NYU Langone Health 2017-04-30
NCT03346941 Side Effects After Direct-acting Antiviral Treatment https://ClinicalTrials.gov/show/NCT03346941 Completed Hospices Civils de Lyon 2017-09-30
NCT01957085 Undiagnosed Hepatitis C Infection in an Urban Hospital https://ClinicalTrials.gov/show/NCT01957085 Completed Temple University 2015-12-31
NCT01732848 A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) https://ClinicalTrials.gov/show/NCT01732848 Completed Bristol-Myers Squibb 2014-06-30
NCT04191018 GastrOesophageal Varices After Sustained Virological Response https://ClinicalTrials.gov/show/NCT04191018 Recruiting Oswaldo Cruz Foundation 2022-08-14
NCT02850289 APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin https://ClinicalTrials.gov/show/NCT02850289 Completed Hoffmann-La Roche 2008-10-31
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium https://ClinicalTrials.gov/show/NCT02581163 Completed AbbVie 2018-02-12
NCT02581020 The Durability of Response and Persistence of Resistance to AbbVie’s 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects https://ClinicalTrials.gov/show/NCT02581020 Active, not recruiting AbbVie 2020-12-31
NCT02578693 Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) https://ClinicalTrials.gov/show/NCT02578693 Recruiting Humanity and Health Research Centre 2020-12-31
NCT02515279 An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria https://ClinicalTrials.gov/show/NCT02515279 Completed Hoffmann-La Roche 2014-12-31
NCT02368522 Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU) https://ClinicalTrials.gov/show/NCT02368522 Completed Bristol-Myers Squibb 2017-02-28
NCT01959321 An Observational Study of Hepatitis C Virus in Pregnancy https://ClinicalTrials.gov/show/NCT01959321 Active, not recruiting The George Washington University Biostatistics Center 2020-12-31
NCT02505243 Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens https://ClinicalTrials.gov/show/NCT02505243 Completed Radboud University 2016-06-30
NCT00770198 sgp130 in Chronic Human Liver Disease https://ClinicalTrials.gov/show/NCT00770198 Completed Erasme University Hospital 2007-01-31
NCT00751426 Treatment of Hepatitis C in Psychiatric Patients https://ClinicalTrials.gov/show/NCT00751426 Completed Charite University, Berlin, Germany 2002-02-28
NCT00747539 Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy https://ClinicalTrials.gov/show/NCT00747539 Completed University of California, Los Angeles 2015-06-30
NCT00736242 Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) https://ClinicalTrials.gov/show/NCT00736242 Completed Merck Sharp & Dohme Corp. 2011-12-31
NCT00727311 Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) https://ClinicalTrials.gov/show/NCT00727311 Completed Merck Sharp & Dohme Corp. 2009-06-30
NCT00728494 Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) https://ClinicalTrials.gov/show/NCT00728494 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00726557 Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) https://ClinicalTrials.gov/show/NCT00726557 Completed Merck Sharp & Dohme Corp. 2009-01-31
NCT00725751 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) https://ClinicalTrials.gov/show/NCT00725751 Completed Merck Sharp & Dohme Corp. 2011-03-31
NCT00725205 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) https://ClinicalTrials.gov/show/NCT00725205 Completed Merck Sharp & Dohme Corp. 2010-10-31
NCT00724295 Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) https://ClinicalTrials.gov/show/NCT00724295 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00724893 Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) https://ClinicalTrials.gov/show/NCT00724893 Completed Merck Sharp & Dohme Corp. 2012-08-31
NCT00724854 Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) https://ClinicalTrials.gov/show/NCT00724854 Completed Merck Sharp & Dohme Corp. 2009-09-30
NCT00724230 Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) https://ClinicalTrials.gov/show/NCT00724230 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00723892 Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) https://ClinicalTrials.gov/show/NCT00723892 Completed Merck Sharp & Dohme Corp. 2009-05-31
NCT00724464 Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) https://ClinicalTrials.gov/show/NCT00724464 Completed Merck Sharp & Dohme Corp. 2010-10-31
NCT00724451 Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) https://ClinicalTrials.gov/show/NCT00724451 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT00724373 Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) https://ClinicalTrials.gov/show/NCT00724373 Completed Merck Sharp & Dohme Corp. 2009-02-28
NCT00723645 Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) https://ClinicalTrials.gov/show/NCT00723645 Completed Merck Sharp & Dohme Corp. 2010-04-30
NCT00723632 Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) https://ClinicalTrials.gov/show/NCT00723632 Completed Merck Sharp & Dohme Corp. 2010-12-31
NCT00710801 Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation https://ClinicalTrials.gov/show/NCT00710801 Completed University of Alberta NA
NCT00709059 Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) https://ClinicalTrials.gov/show/NCT00709059 Completed Merck Sharp & Dohme Corp. 2009-12-31
NCT00709228 Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793) https://ClinicalTrials.gov/show/NCT00709228 Completed Merck Sharp & Dohme Corp. 2008-11-30
NCT00705666 Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705666 Completed Merck Sharp & Dohme Corp. 2008-07-31
NCT00707603 Chronic Hepatitis C and Insulin Resistance https://ClinicalTrials.gov/show/NCT00707603 Completed Garvan Institute of Medical Research 2008-12-31
NCT00704964 Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) https://ClinicalTrials.gov/show/NCT00704964 Completed Merck Sharp & Dohme Corp. 2009-10-31
NCT00704717 Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) https://ClinicalTrials.gov/show/NCT00704717 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00704522 Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) https://ClinicalTrials.gov/show/NCT00704522 Completed Merck Sharp & Dohme Corp. 2009-04-30
NCT00705263 Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705263 Completed Schering-Plough 2008-05-31
NCT00705224 Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) https://ClinicalTrials.gov/show/NCT00705224 Completed Merck Sharp & Dohme Corp. 2010-08-31
NCT00703560 Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients https://ClinicalTrials.gov/show/NCT00703560 Completed University of Texas Southwestern Medical Center 2011-09-30
NCT00700401 POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). https://ClinicalTrials.gov/show/NCT00700401 Completed Hoffmann-La Roche 2010-11-30
NCT00674492 Hepatitis C Virus (HCV) Treatment Completion or Withdrawal https://ClinicalTrials.gov/show/NCT00674492 Completed VA Office of Research and Development 2008-08-31
NCT00659256 Hepatitis C Treatment and Atherosclerosis https://ClinicalTrials.gov/show/NCT00659256 Completed National Institutes of Health Clinical Center (CC) NA
NCT00610597 Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease https://ClinicalTrials.gov/show/NCT00610597 Completed Erasme University Hospital 2007-01-31
NCT00606528 FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy https://ClinicalTrials.gov/show/NCT00606528 Completed University Health Network, Toronto 2013-07-31
NCT00527774 Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients https://ClinicalTrials.gov/show/NCT00527774 Completed St. Martin De Porress Hospital 2008-02-29
NCT00514111 Factors Associated to Success of Hepatitis C Therapy https://ClinicalTrials.gov/show/NCT00514111 Completed UPECLIN HC FM Botucatu Unesp 2008-07-31
NCT00494936 Effects of HIV and Hepatitis C Virus on the Brain https://ClinicalTrials.gov/show/NCT00494936 Completed Icahn School of Medicine at Mount Sinai 2009-07-31
NCT00473993 Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland https://ClinicalTrials.gov/show/NCT00473993 Completed Seidenberg, Arztpraxis A., M.D. NA
NCT00466336 Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices https://ClinicalTrials.gov/show/NCT00466336 Completed National Taiwan University Hospital 2006-12-31
NCT00466271 Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study https://ClinicalTrials.gov/show/NCT00466271 Completed National Taiwan University Hospital 2008-11-30
NCT00444002 Oxidative Stress and Fatty Acids in Hepatitis C https://ClinicalTrials.gov/show/NCT00444002 Completed University Health Network, Toronto 2008-07-31
NCT00435201 Characterization of Clonal B Cell Populations in HCV Infection https://ClinicalTrials.gov/show/NCT00435201 Completed Rockefeller University 2013-06-30
NCT00422838 Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. https://ClinicalTrials.gov/show/NCT00422838 Completed Foundation for Liver Research 2010-06-30
NCT00342641 Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers https://ClinicalTrials.gov/show/NCT00342641 Completed National Institutes of Health Clinical Center (CC) NA
NCT00368225 Transplant-Related Accelerated Progression of Hepatitis C https://ClinicalTrials.gov/show/NCT00368225 Completed National Institutes of Health Clinical Center (CC) NA
NCT00361179 Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00361179 Completed National Taiwan University Hospital NA
NCT00348660 Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic https://ClinicalTrials.gov/show/NCT00348660 Completed St. Michael’s Hospital, Toronto 2010-10-31
NCT00322179 Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00322179 Completed Palo Alto Veterans Institute for Research 2007-11-30
NCT00247884 Pender Assisted Therapy (PATh) - Prospective Study of the Treatment of HCV https://ClinicalTrials.gov/show/NCT00247884 Completed University of British Columbia NA
NCT00237432 Study of the Immune Response to Hepatitis C Virus https://ClinicalTrials.gov/show/NCT00237432 Completed Rockefeller University NA
NCT00227149 Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00227149 Completed University of Wuerzburg NA
NCT00219999 Hepatitis C Virus and the Humoral Immune System https://ClinicalTrials.gov/show/NCT00219999 Completed Rockefeller University 2013-05-31
NCT00216775 Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00216775 Completed Kyoto University 2008-05-31
NCT00205075 Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression https://ClinicalTrials.gov/show/NCT00205075 Completed University of Wisconsin, Madison 2008-06-30
NCT00187473 Natural History of Hepatitis C in Patients With Normal Liver Tests https://ClinicalTrials.gov/show/NCT00187473 Active, not recruiting University of California, San Francisco 2020-12-31
NCT00170131 MMF Influence on HCV Viral Evolution After Liver Transplantation https://ClinicalTrials.gov/show/NCT00170131 Completed Mayo Clinic 2007-07-31
NCT00150904 Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP) https://ClinicalTrials.gov/show/NCT00150904 Completed UMC Utrecht 2008-09-30
NCT00136214 Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects https://ClinicalTrials.gov/show/NCT00136214 Completed Beth Israel Deaconess Medical Center 2008-01-31
NCT00096733 Adult-to-Adult Living Donor Liver Transplantation Study https://ClinicalTrials.gov/show/NCT00096733 Completed Arbor Research Collaborative for Health 2010-08-31
NCT00076427 Leukapheresis for Research on HCV-Coinfected Patients https://ClinicalTrials.gov/show/NCT00076427 Completed National Institutes of Health Clinical Center (CC) NA
NCT00071916 Racial Difference in HCV/Host Interactions https://ClinicalTrials.gov/show/NCT00071916 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00059397 Hepatitis C: Grading and Staging by MR https://ClinicalTrials.gov/show/NCT00059397 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA
NCT00004851 Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies https://ClinicalTrials.gov/show/NCT00004851 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001982 History of Hepatitis C in Volunteer Blood Donors https://ClinicalTrials.gov/show/NCT00001982 Completed National Institutes of Health Clinical Center (CC) NA
NCT00037076 Prevalence of Hepatitis C Virus Infection in HIV-Infected Children https://ClinicalTrials.gov/show/NCT00037076 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00727259 Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) https://ClinicalTrials.gov/show/NCT00727259 Completed Merck Sharp & Dohme Corp. 2008-04-30
NCT00021632 Effects of Ribavirin on Zidovudine or Stavudine https://ClinicalTrials.gov/show/NCT00021632 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00819026 Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors https://ClinicalTrials.gov/show/NCT00819026 Completed University of Wisconsin, Madison 2013-08-31
NCT00006643 Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus https://ClinicalTrials.gov/show/NCT00006643 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00001117 A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection https://ClinicalTrials.gov/show/NCT00001117 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00723931 PegIntron Injection Surveillance Plan (Study P04123) https://ClinicalTrials.gov/show/NCT00723931 Completed Merck Sharp & Dohme Corp. 2009-11-30
NCT00007709 To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI). https://ClinicalTrials.gov/show/NCT00007709 Completed VA Office of Research and Development NA
NCT00007371 Hepatitis C in Clinically Discordant Hemophilic Siblings https://ClinicalTrials.gov/show/NCT00007371 Completed University of North Carolina, Chapel Hill 2004-08-31
NCT00005657 Genetics of Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT00005657 Completed National Institutes of Health Clinical Center (CC) NA
NCT00006301 Immune Response to Hepatitis C Virus https://ClinicalTrials.gov/show/NCT00006301 Completed National Institutes of Health Clinical Center (CC) NA
NCT00004846 Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV https://ClinicalTrials.gov/show/NCT00004846 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001712 Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan https://ClinicalTrials.gov/show/NCT00001712 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04460157 Prediction of Liver-related Outcomes After HCV Cure https://ClinicalTrials.gov/show/NCT04460157 Recruiting Hospital Universitario de Valme 2021-05-31
NCT03111966 Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort https://ClinicalTrials.gov/show/NCT03111966 Completed Hepa C 2017-04-30
NCT03025074 Blood Collection Biorepository for Liver Disease Research https://ClinicalTrials.gov/show/NCT03025074 Recruiting State University of New York at Buffalo 2099-12-31
NCT02971488 The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID https://ClinicalTrials.gov/show/NCT02971488 Completed Hospital Universitario Infanta Leonor 2018-12-31
NCT02969668 Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients https://ClinicalTrials.gov/show/NCT02969668 Active, not recruiting Universitätsklinikum Hamburg-Eppendorf 2018-10-31
NCT02828254 A Follow-up Evaluation Study of PRI-724-1101 https://ClinicalTrials.gov/show/NCT02828254 Completed Komagome Hospital 2017-03-27
NCT02699736 EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV https://ClinicalTrials.gov/show/NCT02699736 Enrolling by invitation Rigshospitalet, Denmark 2030-12-31
NCT02628717 Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) https://ClinicalTrials.gov/show/NCT02628717 Completed Medical University of Vienna 2016-12-31
NCT02510300 A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials https://ClinicalTrials.gov/show/NCT02510300 Enrolling by invitation Gilead Sciences 2024-11-30
NCT02292706 A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT02292706 Active, not recruiting Gilead Sciences 2023-01-31
NCT02250001 Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02250001 Completed Bristol-Myers Squibb 2017-01-20
NCT03356405 Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV https://ClinicalTrials.gov/show/NCT03356405 Active, not recruiting University of Dundee 2023-12-31
NCT02004379 Register of Telaprevir and Boceprevir in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT02004379 Completed Andalusian Network for Design and Translation of Advanced Therapies 2015-06-30
NCT01908660 Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions https://ClinicalTrials.gov/show/NCT01908660 Completed Valme University Hospital 2015-09-30
NCT01846494 Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) https://ClinicalTrials.gov/show/NCT01846494 Completed Duke University 2018-03-19
NCT04301882 An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04301882 Recruiting Beijing Ditan Hospital 2020-09-01
NCT04211844 Metabolic Changes in Chronic HCV Patients Receiving DAAS https://ClinicalTrials.gov/show/NCT04211844 Recruiting Ain Shams University 2020-04-30
NCT04062253 Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid https://ClinicalTrials.gov/show/NCT04062253 Recruiting Hospital Universitario Infanta Leonor 2020-02-15
NCT03775798 Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV. https://ClinicalTrials.gov/show/NCT03775798 Recruiting Austral University, Argentina 2020-12-01
NCT03587714 Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients https://ClinicalTrials.gov/show/NCT03587714 Completed Assiut University 2017-12-01
NCT03566966 Autoantibodies and Direct-acting Antivirals https://ClinicalTrials.gov/show/NCT03566966 Completed University of Bari 2016-08-31
NCT02727933 Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea https://ClinicalTrials.gov/show/NCT02727933 Recruiting Bristol-Myers Squibb 2020-09-30
NCT03226509 Transforming the Cascade Of Hepatitis C Care https://ClinicalTrials.gov/show/NCT03226509 Active, not recruiting University of Pittsburgh 2019-09-30
NCT00114712 The Ribavirin Pregnancy Registry https://ClinicalTrials.gov/show/NCT00114712 Recruiting Syneos Health 2028-12-31